Watch More Highlights

Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses key data that advanced practitioners need to know about treatment for patients with acute lymphocytic leukemia, the shift away from intensive chemotherapy with the use of monoclonal antibodies and tyrosine kinase inhibitors, and whether overall responses and survival can be maintained or improved.

Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.